SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently the center of community attention following a massive $266 million contract award from the U.S. Space Force for suborbital launch missions, which many investors view as a pivotal validation of the company's defense capabilities. Despite this bullish news, community discourse is heavily focused on the stock's frustrating price action, as investors debate whether the current volatility is caused by broader sector instability linked to SpaceX or persistent market manipulation.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp is trending following recent community debate surrounding the company's progress on its Tanbreez project and its involvement in the Kenya tender process, fueling intense scrutiny of its management and communication transparency. Investors are actively discussing the stock's volatility in the context of broader critical mineral sector fluctuations and evolving U.S. government policy toward domestic and Western-allied rare earth supply chains.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors prepare for a pivotal FDA advisory committee meeting on July 29, which will evaluate the regulatory outlook for its Duchenne muscular dystrophy treatment, deramiocel. The community is actively debating the potential for a dual-indication label, the impact of high short interest on future volatility, and the overall significance of recent positive clinical data in the face of ongoing regulatory scrutiny.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is rallying sharply following a significant $53 million private placement announcement, sparking intense retail interest and heavy trading volume. The community is actively debating the potential for further momentum versus the risks of dilution, with many focused on whether the stock can sustain its breakout levels.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is seeing heightened community discussion and volatility following conservative full-year revenue guidance that triggered significant price movement. Investors are closely monitoring the commercial rollout of Vevye and the upcoming retina product launches, debating whether the current share price dip represents a compelling long-term buying opportunity or a signal of continued execution challenges.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is currently trending as investors weigh volatile crude oil prices against the latest geopolitical developments regarding U.S.-Iran negotiations and ongoing regional instability. The community is actively debating whether recent diplomatic headlines are a genuine catalyst for a long-term supply shift or merely speculative noise, with many traders focusing on the impact of potential supply gluts and the effectiveness of energy-related ceasefire agreements.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X ETF

Direxion Daily S&P Biotech Bear 3X Shares

LABD is experiencing significant volatility and high trading volume as investors react to the biotech sector's struggle with rising inflation, elevated oil prices, and broader market uncertainty. Community discussions remain polarized, with many traders debating the effectiveness of shorting the sector through leveraged ETFs while monitoring key technical resistance levels in the XBI biotech index.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is facing intense selling pressure following a leadership transition and concerns over competitive data in the multiple myeloma space. While community sentiment remains divided between fears of further downside and optimism for a potential buyout, many investors are focused on the company's strong CARVYKTI sales and cash position as reasons for a long-term turnaround.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as investors digest news of a potential multi-billion dollar acquisition of Delivery Hero, a move seen as a major strategic effort to expand global scale despite concerns over regulatory hurdles and integration costs. The community is actively debating the stock's long-term potential versus near-term stagnant price action, with many weighing the impact of autonomous vehicle competition against the company's established dominance as a platform aggregator.

ProShares Trust - ProShares K-1 Free Crude Oil ETF

ProShares K-1 Free Crude Oil Strategy ETF

ProShares K-1 Free Crude Oil Strategy ETF is currently capturing community attention as investors debate the impact of significant global supply increases, rising inventory levels, and a growing surplus of crude oil despite ongoing geopolitical tensions. Market sentiment is heavily focused on the tension between reports of potential production growth from key players and the broader shift toward alternative energy sources, fueling active speculation about future price volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Star Equity Holdings (STRR) Reports Q1 Loss, Misses Revenue Estimates

Star Equity Holdings (STRR) delivered earnings and revenue surprises of -395.00% and -4.77%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Griffon (GFF) Q2 Earnings and Revenues Surpass Estimates

Griffon (GFF) delivered earnings and revenue surprises of +6.46% and +2.17%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Carlisle (CSL) Beats Q1 Earnings Estimates

Carlisle (CSL) delivered earnings and revenue surprises of +9.83% and -0.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Insider Selling: Star Equity (NASDAQ:STRR) CEO Sells 7,722 Shares of Stock

Star Equity Holdings, Inc. (NASDAQ:STRR - Get Free Report) CEO Jeffrey Eberwein sold 7,722 shares of the stock in a transaction on Monday, March 30th. The shares were sold at an average price of $9.95, for a total value of $76,833.90. Following the sale, the chief executive officer owned 764,217...

Star Equity (NASDAQ:STRR) Director Louis Parks Acquires 1,500 Shares

Star Equity Holdings, Inc. (NASDAQ:STRR - Get Free Report) Director Louis Parks purchased 1,500 shares of the stock in a transaction on Friday, March 27th. The stock was acquired at an average cost...

Looking for a Growth Stock? 3 Reasons Why Star Equity Holdings (STRR) is a Solid Choice 

Star Equity Holdings (STRR) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Wall Street Analysts Believe Star Equity Holdings (STRR) Could Rally 92.31%: Here's is How to Trade

The consensus price target hints at a 92.3% upside potential for Star Equity Holdings (STRR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Star Equity Holdings (STRR) Reports Q4 Loss, Lags Revenue Estimates

Star Equity Holdings (STRR) delivered earnings and revenue surprises of -169.78% and -3.28%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Star Equity Holdings (STRR) to Report Q4 Results: Wall Street Expects Earnings Growth

Star Equity Holdings (STRR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insider Buying: Star Equity (NASDAQ:STRR) CEO Purchases 1,977 Shares of Stock

Star Equity Holdings, Inc. (NASDAQ:STRR - Get Free Report) CEO Jeffrey Eberwein bought 1,977 shares of the business's stock in a transaction on Wednesday, December 31st. The shares were acquired at...

Star Equity Holdings, Inc. is a diversified holding company, that seeks to build long-term shareholder value by acquiring, managing, and growing businesses with strong fundamentals and market opportunities. Its current structure consists of four divisions: Building Solutions, Business Services, Energy Services, and Investments. The company was founded in 2003 and is headquartered in Old Greenwich, CT.

Star Equity Holdings Inc.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.07	--	--	N/A
Q1 '26	$0.05	-$0.99	-2080.00%	MISSED
Q4 '25	$0.18	-$0.10	-155.56%	MISSED
Q3 '25	$0.32	$0.02	-93.75%	MISSED
Q2 '25	-$0.60	$0.12	120.00%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

STRRStar Equity Holdings Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest STRR News